JERUSALEM, July 12, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced its CEO, Ophir Shahaf, was interviewed by the Wall Street Reporter. The interview discusses key trends in the biotech industry, recent portfolio updates, future business strategy and more.
To listen to the interview click here, http://bit.ly/Mn5zRD, or access the interview directly from the Wall Street Reporter website.
About Hadasit Bio Holdings
Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.
Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. Its portfolio companies develop drugs with blockbuster potential (with markets worth over one billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.
HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.
For more information please visit: www.hbl.co.il
KCSA Strategic Communications
Rob Fink / Josh Dver
212.896.1206 / 1239
email@example.com / firstname.lastname@example.org
SOURCE Hadasit Bio-Holdings Ltd.